

Roberta Lanzillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/664421/publications.pdf>

Version: 2024-02-01

164
papers

4,340
citations

134610

34
h-index

182931

54
g-index

168
all docs

168
docs citations

168
times ranked

5823
citing authors

#	ARTICLE	IF	CITATIONS
1	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 93-101.	1.4	13
2	Cognitive trajectories in multiple sclerosis: a long-term follow-up study. <i>Neurological Sciences</i> , 2022, 43, 1215-1222.	0.9	9
3	Disability assessment using Google Maps. <i>Neurological Sciences</i> , 2022, 43, 1007-1014.	0.9	10
4	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
5	Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103431.	0.9	5
6	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. <i>European Radiology</i> , 2022, , 1.	2.3	4
7	Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience. <i>Journal of Clinical Psychology in Medical Settings</i> , 2022, 29, 798-807.	0.8	2
8	Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach. <i>European Radiology</i> , 2022, 32, 5382-5391.	2.3	13
9	Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). <i>Multiple Sclerosis Journal</i> , 2022, 28, 597-607.	1.4	10
10	Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2081.	1.0	6
11	Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2022, 12, 109-116.	1.2	5
12	Editorial to Special Issue "Cognitive Involvement in Multiple Sclerosis". <i>Brain Sciences</i> , 2022, 12, 561.	1.1	0
13	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103814.	0.9	2
14	A polynomial regression-based approach to estimate relaxation rate maps suitable for multiparametric segmentation of clinical brain MRI studies in multiple sclerosis. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 223, 106957.	2.6	2
15	Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102636.	0.9	29
16	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
17	The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 893-900.	1.7	28
18	Digital work engagement among Italian neurologists. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110296.	1.1	7

#	ARTICLE	IF	CITATIONS
19	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
20	Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis – a case report. <i>Neurological Sciences</i> , 2021, 42, 37-39.	0.9	4
21	Public Engagement and Neurology: An Update. <i>Brain Sciences</i> , 2021, 11, 429.	1.1	5
22	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 1234.	1.0	10
23	Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 346.	1.1	23
24	A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 502.	1.1	9
25	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	2.1	24
26	Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102802.	0.9	25
27	Unraveling Deep Gray Matter Atrophy and Iron and Myelin Changes in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2021, 42, 1223-1230.	1.2	19
28	Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review. <i>Children</i> , 2021, 8, 445.	0.6	7
29	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117430.	0.3	1
30	Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis. <i>International Neurology Journal</i> , 2021, 25, 310-318.	0.5	6
31	Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2328.	1.0	19
32	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.3	9
33	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
34	Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data. <i>PLoS ONE</i> , 2021, 16, e0258017.	1.1	1
35	A Combined Radiomics and Machine Learning Approach to Overcome the Clinico-radiologic Paradox in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2021, 42, 1927-1933.	1.2	9
36	Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5756.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	1.4	38
38	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
39	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	2.1	39
40	The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101514.	0.9	9
41	Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101871.	0.9	18
42	COVIDâ€“19 pandemic and mental distress in multiple sclerosis: implications for clinical management. <i>European Journal of Neurology</i> , 2020, 28, 3375-3383.	1.7	47
43	Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2020, 26, 1533-1536.	1.6	55
44	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	0.9	5
45	A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. <i>Brain Sciences</i> , 2020, 10, 453.	1.1	5
46	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
47	Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102452.	0.9	37
48	Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). <i>BMC Health Services Research</i> , 2020, 20, 797.	0.9	12
49	Cladribine vs other drugs in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	32
50	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. <i>Journal of Clinical Medicine</i> , 2020, 9, 4066.	1.0	19
51	Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015â€“2017 Prevalence. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3388.	1.2	13
52	Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102211.	0.9	6
53	A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. <i>Neurological Sciences</i> , 2020, 41, 3235-3241.	0.9	9
54	Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials. <i>Frontiers in Neurology</i> , 2020, 11, 489.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	1.8	19
56	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102282.	0.9	10
57	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	0.9	4
58	Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. <i>Journal of Neurology</i> , 2020, 267, 1737-1743.	1.8	12
59	The Use of Social Media and Digital Devices Among Italian Neurologists. <i>Frontiers in Neurology</i> , 2020, 11, 583.	1.1	18
60	Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 542.	1.1	35
61	2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis. <i>European Radiology</i> , 2020, 30, 3813-3822.	2.3	18
62	Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis. <i>NeuroImage: Clinical</i> , 2020, 26, 102201.	1.4	4
63	Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101963.	0.9	14
64	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0
65	Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116782.	0.3	2
66	Assessing disability and relapses in multiple sclerosis on tele-neurology. <i>Neurological Sciences</i> , 2020, 41, 1369-1371.	0.9	65
67	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	1.4	36
68	Retinal vascular density in multiple sclerosis: a 1-year follow-up. <i>European Journal of Neurology</i> , 2019, 26, 198-201.	1.7	28
69	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	0.9	23
70	Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. <i>PLoS ONE</i> , 2019, 14, e0222012.	1.1	14
71	Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10. <i>Brain Sciences</i> , 2019, 9, 259.	1.1	4
72	“Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44

#	ARTICLE	IF	CITATIONS
73	Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon- β 1a-treated multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641881907.	1.5	35
74	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz445.	0.4	21
75	Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 18074.	1.6	28
76	Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. <i>American Journal of Neuroradiology</i> , 2019, 40, 99-106.	1.2	39
77	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. <i>Journal of Neurology</i> , 2019, 266, 707-716.	1.8	14
78	MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. <i>Neuroradiology</i> , 2019, 61, 155-162.	1.1	38
79	Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 193-196.	0.9	12
80	Normative values of the Rao's Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education. <i>Neurological Sciences</i> , 2019, 40, 713-717.	0.9	3
81	Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. <i>Journal of Neurology</i> , 2019, 266, 361-368.	1.8	9
82	Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 1-6.	0.9	25
83	Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 300-301.	1.4	11
84	Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 108-109.	0.9	11
85	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.5	102
86	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.5	74
87	Cardiovascular profile improvement during Natalizumab treatment. <i>Metabolic Brain Disease</i> , 2018, 33, 981-986.	1.4	5
88	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
89	Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1706-1714.	1.4	88
90	A 8-year retrospective cohort study comparing Interferon- β formulations for relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 50-54.	0.9	8

#	ARTICLE	IF	CITATIONS
91	Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. <i>Brain and Behavior</i> , 2018, 8, e01121.	1.0	13
92	e-Health and multiple sclerosis: An update. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1657-1664.	1.4	63
93	Clinical activity after fingolimod cessation: disease reactivation or rebound?. <i>European Journal of Neurology</i> , 2018, 25, 1270-1275.	1.7	56
94	Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?. <i>Journal of Neurology</i> , 2018, 265, 2260-2266.	1.8	20
95	Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 175-178.	0.9	49
96	Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience. <i>Quality of Life Research</i> , 2017, 26, 727-736.	1.5	55
97	Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 28-32.	0.9	21
98	The importance of being persistent to multiple sclerosis treatments. <i>Journal of Clinical Neuroscience</i> , 2017, 40, 198-199.	0.8	0
99	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. <i>Neuroradiology</i> , 2017, 59, 563-570.	1.1	30
100	CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2017, 309, 47-50.	1.1	24
101	What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials. <i>European Journal of Neurology</i> , 2017, 24, 661-662.	1.7	2
102	A longitudinal real-life comparison study of natalizumab and fingolimod. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 217-222.	1.0	19
103	Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β -1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis. <i>European Journal of Neurology</i> , 2017, 24, 446-449.	1.7	2
104	Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. <i>Clinical Immunology</i> , 2017, 183, 249-253.	1.4	11
105	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon- β 1a using RebiSmart, "the FUTURE study. <i>Neurological Sciences</i> , 2017, 38, 1999-2005.	0.9	15
106	Assessing association of comorbidities with treatment choice and persistence in MS. <i>Neurology</i> , 2017, 89, 2222-2229.	1.5	50
107	Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression. <i>European Journal of Neurology</i> , 2017, 24, 195-204.	1.7	12
108	The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1289-1296.	1.4	43

#	ARTICLE	IF	CITATIONS
109	Predictors of the 10-year direct costs for treating multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 522-528.	1.0	16
110	Cerebellar lobule atrophy and disability in progressive MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1065-1072.	0.9	47
111	Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. <i>PLoS ONE</i> , 2017, 12, e0169489.	1.1	13
112	Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach. <i>Interactive Journal of Medical Research</i> , 2017, 6, e10.	0.6	36
113	Social Media and Multiple Sclerosis in the Posttruth Age. <i>Interactive Journal of Medical Research</i> , 2017, 6, e18.	0.6	22
114	SPG5 and multiple sclerosis: clinical and genetic overlap?. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 410-414.	1.0	2
115	Google Trends: new evidence for seasonality of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1028-1029.	0.9	39
116	Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable <i>Haemophilus influenzae</i> . <i>Scientific Reports</i> , 2016, 6, 39430.	1.6	23
117	Mobitz type I and II atrioventricular blocks during fingolimod therapy. <i>Neurological Sciences</i> , 2016, 37, 1557-1559.	0.9	5
118	The Dress: Transforming a web viral event into a scientific survey. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 41-46.	0.9	16
119	The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region. <i>Neurological Sciences</i> , 2016, 37, 315-322.	0.9	3
120	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016, 87, 1066-1066.	1.5	2
121	The use of medical-grade cannabis in patients non-responders to Nabiximols. <i>Journal of the Neurological Sciences</i> , 2016, 368, 349-351.	0.3	9
122	Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 90-96.	0.9	21
123	Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study. <i>British Journal of Radiology</i> , 2016, 89, 20160321.	1.0	8
124	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1b therapy in relapsing and remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173.	1.4	24
125	Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 921-925.	1.4	16
126	In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents. <i>European Radiology</i> , 2016, 26, 4577-4584.	2.3	73

#	ARTICLE	IF	CITATIONS
127	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
128	Quality of life and cognitive functions in early onset multiple sclerosis. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 158-163.	0.7	36
129	Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. <i>Multiple Sclerosis Journal</i> , 2016, 22, 659-667.	1.4	107
130	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0120754.	1.1	31
131	Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. <i>Journal of Neurology</i> , 2015, 262, 961-967.	1.8	29
132	Uric acid: a potential biomarker of multiple sclerosis and of its disability. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 753-9.	1.4	38
133	The Framingham cardiovascular risk score in multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 1176-1183.	1.7	54
134	Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1215-1216.	1.4	6
135	JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 807.	0.9	11
136	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 220-226.	1.4	30
137	Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab. <i>JAMA Neurology</i> , 2014, 71, 954.	4.5	50
138	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 82, 41-48.	1.5	128
139	Internal Jugular Vein Blood Flow in Multiple Sclerosis Patients and Matched Controls. <i>PLoS ONE</i> , 2014, 9, e92730.	1.1	18
140	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. <i>BMC Neurology</i> , 2013, 13, 20.	0.8	19
141	Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. <i>Neurological Sciences</i> , 2013, 34, 521-528.	0.9	20
142	Multiple Sclerosis: Cerebral Circulation Time. <i>Radiology</i> , 2012, 262, 947-955.	3.6	42
143	Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 306-314.	1.0	25
144	Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature. <i>Pharmacology & Pharmacy</i> , 2012, 03, 248-253.	0.2	1

#	ARTICLE	IF	CITATIONS
145	Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. <i>European Journal of Neurology</i> , 2011, 18, 1402-1406.	1.7	17
146	Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. <i>Neurological Sciences</i> , 2011, 32, 287-292.	0.9	4
147	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 450-454.	1.4	79
148	A voxel-based morphometry study of disease severity correlates in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 45-54.	1.4	45
149	Early detection of biventricular involvement in myotonic dystrophy by tissue Doppler. <i>International Journal of Cardiology</i> , 2007, 118, 227-232.	0.8	19
150	Multiple sclerosis and headache co-morbidity. A case-control study. <i>Neurological Sciences</i> , 2007, 28, 133-135.	0.9	54
151	Grey matter loss in relapsing-remitting multiple sclerosis: A voxel-based morphometry study. <i>NeuroImage</i> , 2006, 29, 859-867.	2.1	167
152	Modifications of brain tissue volumes in facioscapulohumeral dystrophy. <i>NeuroImage</i> , 2006, 32, 1237-1242.	2.1	26
153	Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. <i>Journal of the Neurological Sciences</i> , 2006, 245, 141-145.	0.3	27
154	Early onset calpainopathy with normal non-functional calpain 3 level. <i>Developmental Medicine and Child Neurology</i> , 2006, 48, 304-306.	1.1	15
155	Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. <i>European Journal of Neurology</i> , 2006, 13, 1014-1021.	1.7	30
156	A new POLG1 mutation with peripheral and severe axonal and demyelinating sensory-motor neuropathy. <i>Journal of Neurology</i> , 2006, 253, 869-874.	1.8	23
157	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 167, 131-137.	1.1	56
158	Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. <i>Annals of Human Genetics</i> , 2005, 69, 253-9.	0.3	35
159	Epileptic seizures in multiple sclerosis: clinical and EEG correlations. <i>Neurological Sciences</i> , 2003, 24, 322-328.	0.9	49
160	Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. <i>NeuroImage</i> , 2003, 18, 360-366.	2.1	82
161	Two new mutations in the myophosphorylase gene in Italian patients with McArdle's disease. <i>Neuromuscular Disorders</i> , 2002, 12, 498-500.	0.3	7
162	Aphasia as a rare presentation of monosymptomatic demyelinating disease: case report and review of the literature. <i>Neurological Sciences</i> , 2002, 23, 79-82.	0.9	19

#	ARTICLE	IF	CITATIONS
163	Transient Muteness Followed by Dysarthria in Patients with Pontomesencephalic Stroke. Cerebrovascular Diseases, 1999, 9, 124-126.	0.8	11
164	Multiple Sclerosis And Maternity: A Psychological Explorative Qualitative Research. Qualitative Report, 0, , .	0.1	1